PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

被引：0
|
作者：
Marzia Del Re
Riccardo Marconcini
Giulia Pasquini
Eleonora Rofi
Caterina Vivaldi
Francesco Bloise
Giuliana Restante
Elena Arrigoni
Chiara Caparello
Maria Grazia Bianco
Stefania Crucitta
Iacopo Petrini
Enrico Vasile
Alfredo Falcone
Romano Danesi
机构：
[1] Clinical Pharmacology and Pharmacogenetics Unit,Department of Clinical and Experimental Medicine
[2] University of Pisa,Department of Translational Research and New Technologies in Medicine and Surgery
[3] Medical Oncology Unit,Department of Translational Research and New Technologies in Surgery and Medicine
[4] University of Pisa,undefined
[5] General pathology,undefined
[6] University of Pisa,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
PD-L1; exosomes; circulating nucleic acids; immunotherapy; predictive biomarker; pharmacogenetics; nivolumab; pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 824
页数：4
相关论文
共 50 条
  • [21] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
    Chen, Gang
    Huang, Alexander C.
    Zhang, Wei
    Zhang, Gao
    Wu, Min
    Xu, Wei
    Yu, Zili
    Yang, Jiegang
    Wang, Beike
    Sun, Honghong
    Xia, Houfu
    Man, Qiwen
    Zhong, Wenqun
    Antelo, Leonardo F.
    Wu, Bin
    Xiong, Xuepeng
    Liu, Xiaoming
    Guan, Lei
    Li, Ting
    Liu, Shujing
    Yang, Ruifeng
    Lu, Youtao
    Dong, Liyun
    McGettigan, Suzanne
    Somasundaram, Rajasekharan
    Radhakrishnan, Ravi
    Mills, Gordon
    Lu, Yiling
    Kim, Junhyong
    Chen, Youhai H.
    Dong, Haidong
    Zhao, Yifang
    Karakousis, Giorgos C.
    Mitchell, Tara C.
    Schuchter, Lynn M.
    Herlyn, Meenhard
    Wherry, E. John
    Xu, Xiaowei
    Guo, Wei
    NATURE, 2018, 560 (7718) : 382 - +
  • [22] PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
    Madore, Jason
    Vilain, Ricardo E.
    Menzies, Alexander M.
    Kakavand, Hojabr
    Wilmott, James S.
    Hyman, Jessica
    Yearley, Jennifer H.
    Kefford, Richard F.
    Thompson, John F.
    Long, Georgina V.
    Hersey, Peter
    Scolyer, Richard A.
    PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (03) : 245 - 253
  • [23] Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects
    Li, Wenyu
    Gu, Junjie
    Fan, Hongwei
    Zhang, Li
    Guo, Jun
    Si, Lu
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 201
  • [24] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
    Patrinely, James R., Jr.
    Baker, Laura X.
    Davis, Elizabeth J.
    Song, Haocan
    Ye, Fei
    Johnson, Douglas B.
    CANCER, 2020, 126 (15) : 3448 - 3455
  • [25] Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy
    Mei, Jie
    Cai, Yun
    Wang, Huiyu
    Xu, Rui
    Zhou, Jiaofeng
    Lu, Jiahui
    Yang, Xuejing
    Pan, Jiadong
    Liu, Chaoying
    Xu, Junying
    Zhu, Yichao
    CLINICAL IMMUNOLOGY, 2023, 246
  • [26] The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
    Zhang, Tengfei
    Xie, Jing
    Arai, Seiji
    Wang, Liping
    Shi, Xuezhong
    Shi, Ni
    Ma, Fen
    Chen, Sen
    Huang, Lan
    Yang, Li
    Ma, Wang
    Zhang, Bin
    Han, Weidong
    Xia, Jianchuan
    Chen, Hu
    Zhang, Yi
    ONCOTARGET, 2016, 7 (45) : 73068 - 73079
  • [27] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [28] Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
    Kim A. Brogden
    Deepak Parashar
    Andrea R. Hallier
    Terry Braun
    Fang Qian
    Naiyer A. Rizvi
    Aaron D. Bossler
    Mohammed M. Milhem
    Timothy A. Chan
    Taher Abbasi
    Shireen Vali
    BMC Cancer, 18
  • [29] Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
    Brogden, Kim A.
    Parashar, Deepak
    Hallier, Andrea R.
    Braun, Terry
    Qian, Fang
    Rizvi, Naiyer A.
    Bossler, Aaron D.
    Milhem, Mohammed M.
    Chan, Timothy A.
    Abbasi, Taher
    Vali, Shireen
    BMC CANCER, 2018, 18
  • [30] Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
    Kirienko, Margarita
    Sollini, Martina
    Chiti, Arturo
    CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (06) : 417 - 427
12345